Yayın:
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170

Sadeleştirilmiş öğe sayfası
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorCatherine Thiéblemont
dc.contributor.authorВ Я Мельниченко
dc.contributor.authorKrimo Bouabdallah
dc.contributor.authorJan Walewski
dc.contributor.authorAlejandro Majlis
dc.contributor.authorLaura Maria Fogliatto
dc.contributor.authorAlejandro Martı́n
dc.contributor.authorBeth Christian
dc.contributor.authorZafer Gülbaş
dc.contributor.authorMuhi̇t Özcan
dc.contributor.authorGuilherme Fleury Perini
dc.contributor.authorHervé Ghesquières
dc.contributor.authorMargaret A. Shipp
dc.contributor.authorSeth Thompson
dc.contributor.authorSamhita Chakraborty
dc.contributor.authorPatricia Marinello
dc.contributor.authorPhilippe Armand
dc.contributor.orcid0000-0002-2112-2651
dc.contributor.orcid0000-0002-9941-2448
dc.contributor.orcid0000-0002-6728-6264
dc.contributor.orcid0000-0002-4425-7823
dc.contributor.orcid0000-0003-4247-2674
dc.contributor.orcid0000-0002-0610-7971
dc.contributor.orcid0000-0001-6330-1028
dc.contributor.orcid0000-0002-4709-0627
dc.contributor.orcid0000-0002-1326-1918
dc.contributor.orcid0000-0001-7235-1334
dc.contributor.orcid0000-0002-3131-3718
dc.contributor.orcid0000-0002-3949-6897
dc.contributor.orcid0000-0001-6098-1603
dc.date.accessioned2025-11-13T09:09:54Z
dc.date.issued2023-05-02
dc.identifier.doihttps://doi.org/10.1182/blood.2022019340
dc.identifier.endpage145
dc.identifier.issn0006-4971
dc.identifier.issue2
dc.identifier.openalexW4367668321
dc.identifier.startpage141
dc.identifier.urihttps://hdl.handle.net/11421/643
dc.identifier.urihttps://doi.org/10.1182/blood.2022019340
dc.identifier.volume142
dc.language.isoen
dc.relation.ispartofBlood
dc.rightsopenAccess
dc.subjectMedicine
dc.subjectNeutropenia
dc.subjectRefractory (planetary science)
dc.subjectInternal medicine
dc.subjectAdverse effect
dc.subjectSurgery
dc.subjectLymphoma
dc.subjectAlemtuzumab
dc.subjectRituximab
dc.subjectTransplantation
dc.subjectPhases of clinical research
dc.subjectGastroenterology
dc.subjectChemotherapy
dc.titlePembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5058571002

Dosyalar

Koleksiyonlar

Publications